Latest News
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
...
Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management
31 March 2026 - Cell-free DNA testing company Natera Inc (NASDAQ:NTRA) on Tuesday reported publication of a prospective study in Clinical Cancer Research demonstrating that its Signatera molecular residual disease (MRD) test can help identify older p...
AstraZeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia
31 March 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) on Tuesday reported positive results from its global Phase III clinical programme evaluating efzimfotase alfa for hypophosphatasia, a rare metabolic disease.The ...
ALK secures EU approval for EURneffy 1 mg as needle-free adrenaline option for children
31 March 2026 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) announced on Tuesday that the European Commission has granted marketing authorisation for EURneffy 1 mg, enabling a needle-free adrenaline treatment for anaphylaxis...
Galapagos and Gilead expand collaboration to advance T cell engager programme
31 March 2026 - Belgian biotechnology company Galapagos NV (Euronext Brussels:GLPG) (NASDAQ:GLPG) announced on Tuesday that it has entered into a binding agreement with US biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) to collaborate on ...